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Abstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation
in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although
there has been significant advancement in antiplatelet therapeutic approaches, aspirin still
remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and
tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen
incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients
have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number
of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and
reversibility. A focused effort in the development of newer antiplatelet therapies to address some
of these shortcomings has resulted in a significant number of potential antiplatelet drugs which
target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins,
protease-activated receptors, thromboxane), and glycoproteins (αIIbβ3, GPVI, vWF, GPIb) in
the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to
be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with
fewer untoward side-effects to what is currently in use today.
Keywords: platelet aggregation inhibitors, blood platelets, purinergic P2Y receptor antagonists,
receptor, PAR-1, platelet glycoprotein GPIIb-IIIa, thrombosis
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Antiplatelet drugs are the cornerstone in treatment of cardiovascular diseases. Despite
the significant decrease in morbidity and mortality due to the currently approved antiplatelet drugs, recurrent ischemia, myocardial infarction (MI), and unwanted bleeding
still occur. The majority of drugs in development have focused on targeting either
surface receptors or enzymes in the platelet in order to protect against unwanted clot
formation following initial platelet activation. The first target for antiplatelet therapy
was cyclooxygenase-1 by aspirin. While newer approaches for containing platelet
activity have been developed, the pharmacodynamics and pharmacoeconomics suggest
that aspirin will continue to be a mainstay for platelet therapy in the years to come.
Currently, a combination regimen of aspirin and clopidogrel is the standard of care
for prevention of platelet activation, thrombosis, and stroke. Unfortunately many of
the current antiplatelet drugs face limitations in their utility due to genetic differences
in the ability to metabolize pro-drugs, such as is the case with clopidogrel, acquired
allergic responses such as is seen with heparin and aspirin, and resistance as has been
reported with aspirin (see Table 1). Additional limitations observed in the application

Journal of Blood Medicine 2012:3 33–42
© 2012 Yeung and Holinstat publisher and licensee Dove Medical Press Ltd. This is an Open Access
article which permits unrestricted noncommercial use, provided the original work is properly cited.

33

Dovepress

Yeung and Holinstat

Table 1 Approved antiplatelet drugs
Drug

Target

Half-life

Side effects

Bioavailability

Use

Ticlopidine
(Ticlid)

P2Y12 receptor

12 hours

Oral

Clopidogrel
(Plavix)

P2Y12 receptor

6–8 hours

Bleeding, rash, neutropenia, thrombotic
thrombocytopenic purpura (rare), nausea,
vomiting, heartburn, indigestion
Bleeding, rash, neutropenia, thrombotic
thrombocytopenic purpura (rare)

Prasugrel
(Effient)
Ticagrelor
(Brilinta)
Abciximab
(ReoPro)
Eptifibatide
(Integrilin)
Tirofiban
(Aggrastat)
Cilostazol
(Pletal)
Dipyridamole
(Aggrenox)

P2Y12 receptor

8 hours

Bleeding

Oral

P2Y12 receptor

6–12 hours

Dyspnea

Oral

Transient ischemic
attacks, patients
undergoing PCI
NSTEMI, STEMI, PCI,
recent stroke, or
established PAD
Patients with ACS
undergoing PCI
STEMI, ACS

GPIIb-IIIa

, 10–30 minutes

IV

PCI

GPIIb-IIIa

∼2.5 hours

IV

GPIIb-IIIa

2 hours

PDE3

11–13 hours

Bleeding, thrombocytopenia, EDTA-induced
psuedothrombocytopenia
Bleeding, thrombocytopenia, EDTA-induced
psuedothrombocytopenia
Bleeding, thrombocytopenia, EDTA-induced
psuedothrombocytopenia
Headache, dizziness, hypotension, flushing,
nausea, vomiting, diarrhea, abdominal pain
Bleeding, headache, diarrhea, palpitations,
dizziness, rash, pancytopenia

NSTEMI, PCI, unstable
angina
NSTEMI, PCI, unstable
angina
Intermittent
claudication, PAD, PCI
Transient ischemic
attacks

PDE3 and inhibition 10 hours
of adenosine uptake

Oral

IV
Oral
Oral

Abbreviations: ACS, acute coronary syndromes; EDTA, ethylenediaminetetraacetic acid; GP, glycoprotein; IV, intravenous; NSTEMI, non-ST elevation myocardial infarction;
PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PDE, phosphodiesterase; STEMI, ST elevation myocardial infarction.

of currently approved antiplatelet drugs include a narrow
therapeutic window and limited efficacy. An overview of
the current Food and Drug Administration (FDA)-approved
antiplatelet therapies as well as those in development will be
discussed in this review.

P2Y receptor antagonists
The P2Y receptors are G-protein-coupled (GPCR) purinergic
receptors belonging to the P2 family. Two receptors, P2Y1
and P2Y12, are present in the platelet. P2Y1 is a Gq coupled
GPCR, while P2Y12 is coupled to Gαi2. Activation of P2Y1
signals phospholipase β, leading to DAG formation, calcium
mobilization, and eventually PKC and CalDAG-GEF activation.1 In contrast, P2Y12 activation inhibits adenylyl cyclase,
activates phosphoinositide 3-kinase,2 the small GTPase
Rap1,3 and activation of αIIbβ3.4
Ticlopidine (Ticlid®; Roche, Basel, Switzerland) is a first
generation thienopyridine that requires cytochrome P450
(CYP) 1 A metabolism prior to exerting its irreversible antagonistic effects on platelet reactivity via the P2Y12 receptor.5
Early experimental observations showed agonist-induced
platelet aggregation was intermittently inhibited by ticlopidine.6,7 Studies with ticlopidine, however, exhibit off-target
effects mediated by the inhibition of intracellular calcium
mobilization.8 Maximal inhibition of platelet aggregation
is observed 3–5 days post administration of ticlopidine.9
The delayed onset of antiplatelet effects is a consequence
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of metabolism of the pro-drug.6 Clinical trials (CATS and
TASS studies) have shown ticlopidine to be more effective
than aspirin alone,10,11 but exhibiting significant off-target
effects including minor bleeding with hemorrhagic events
observed in less than 1% of subjects studied. Additionally,
ticlopidine-treated patients typically discontinue treatment
due to a variety of secondary adverse events including diarrhea, skin rash, and neutropenia.10,12
Clopidogrel (Plavix®, Bristol-Myers Squibb, New York
City, NY), a second generation oral thienopyridine, also
requires metabolism of a pro-drug by the CYP2C19. The
active metabolite, which is a highly labile compound, irreversibly binds to and inhibits the P2Y12 receptor through
a disulfide bridge. The CURE trial has shown the clinical
benefit of the dual clopidogrel-aspirin therapy compared with
aspirin alone by significantly reducing mortality and nonfatal
MI or stroke in patients with unstable angina; however, the
dual regimen was associated with an increase in bleeding
compared with placebo.13,14 The CAPRIE trial, which evaluated the efficacy of clopidogrel monotherapy compared with
dual therapy of clopidogrel plus aspirin, showed clopidogrel
treatment results in a reduction of primary endpoints. 15
Evidence of poor metabolizers for clopidogrel has helped
to explain the reduced function in patients with an altered
CYP2C19 allele.16 Poor metabolizers of clopidogrel have
diminished platelet inhibition resulting in a higher rate of
adverse cardiovascular events than noncarriers.17
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Prasugrel (Effient®, Eli Lilly and Company, Indianapolis,
IN) is a third-generation thienopyridine, chemically distinct
from clopidogrel. In-vivo and in-vitro pharmacological
studies have demonstrated that this adenosine triphosphate
(ATP) analog selectively and irreversibly inhibits adenosine
diphosphate (ADP)-induced aggregation to a greater degree
than clopidogrel.18 The irreversible binding is thought to be
due to the disulfide binding between the reactive thiol group
of the active metabolite and the cysteine residue of the P2Y12
receptor.19–21 Prasugrel is an orally available pro-drug that
requires active transformation via the CYP450 along with
esterases.22 Activation of the pro-drug requires CYP3 A4
and CYP2B6.23 Clinical studies have verified that inhibition of platelet aggregation is more effective with prasugrel
compared with clopidogrel after a single dose in healthy
subjects.23 Furthermore, subjects who responded poorly to
clopidogrel showed greater platelet-induced inhibition in
response to prasugrel.23,24 Further, assessment of secondary
endpoints favors prasugrel due to lower incidences of cardiovascular death, nonfatal MI, and rehospitalization due to
recurrent ischemia.
Ticagrelor (Brillinta ®, AstraZeneca, London, UK),
an oral cyclopentyl-triazolo-pyrimidine analog, unlike
thienopyridines, is a direct and reversible inhibitor of
the P2Y12 receptor that is activated from its pro-drug by
CYP3 A.25 Ticagrelor exerts its action via binding to the
P2Y12 receptor at a site distinct from the ADP binding site,
thus making it an allosteric inhibitor.25 As a consequence of
P2Y12 inhibition, ATP is converted to cyclic monophosphate,
vasodilator-stimulated phospoprotein is dephosphorylated,
and activation of PI3-K is inhibited.26 The PLATO trial
compared ticagrelor with clopidogrel in which the primary
composite endpoints, stroke, MI, cardiovascular death, and
stent thrombosis, were reduced in patients with acute coronary syndromes (ACS) (with or without ST-elevation MI).27
The benefit of ticagrelor appears to be attenuated in patients
with lower bodyweight and those not taking lipid-lowering
drugs in North American groups relative to comparative
studies elsewhere.28 There is no significant difference in
major bleeding between the two agents; however, spontaneous (noncoronary artery bypass grafts) or nonproceduralrelated bleeding is increased with ticagrelor. Additionally,
off-target effects of dyspnea and asymptomatic ventricular
pauses are associated with ticagrelor use.28,29 In general,
ticagrelor has so far proven superior to current treatment
regimens, including a rapid onset of action, acceptable safety
profile, and effectiveness in reducing the primary endpoints
in ACS patients.
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Elinogrel (PRT060128, Novartis, Basel, Switzerland/
Portola Pharmaceuticals, South San Francisco, CA) is a
direct-acting reversible P2Y12 receptor inhibitor that is currently undergoing clinical investigation (INNOVATE-PCI)
for efficacy and safety in patients undergoing percutaneous
coronary intervention (PCI) (see Table 2).30 Preclinical data
show that intravenous or orally administered elinogrel is
superior to clopidogrel and has minimal effect on bleeding
times.31 In addition, a single dose of elinogrel has been shown
to overcome high platelet reactivity in patients undergoing
PCI who were nonresponsive to clopidogrel.31 Elinogrel,
while still in clinical development for safety and efficacy
assessment in patients, shows promise as a next generation
P2Y12 antagonist.
Cangrelor (ARC-69931MX, The Medicines Company,
Parsippany, NJ) is an intravenous nontheinopyridine and
reversible P2Y12 inhibitor. Like prasugrel and ticagrelor,
cangrelor showed a more rapid onset of action and greater
degree of platelet inhibition than clopidogrel. Recent
evaluations of the inhibitor in the CHAMPION-PCI and
CHAMPION-PLATFORM trials were stopped early due to
its lack of apparent differences in the primary endpoint of
death, MI, or ischemia-driven revascularization 48 hours after
PCI.32 Also, the rate of major bleeding in patients undergoing
PCI was higher with cangrelor compared with clopidogrel
in both studies.33
Table 2 Antiplatelet drugs under development
Drug

Target

Stage of development

Elinogrel

P2Y12 receptor

Phase II

Cangrelor

P2Y12 receptor

Phase III

BX 667

P2Y12 receptor

Preclinical

Vorapaxor (SXH 530348)

PAR1

Phase III

Atopaxar (E5555)

PAR1

Phase II

S18886 (Terutroban)

TPα

Phase III

Z-335

TPα

Phase I

BM-573

TPα

Preclinical

h6B4-Fab

GPIb

Preclinical

GPGP-290

GPIbα

Preclinical

SZ2

GPIbα

Preclinical

PR-15 (Revacept)

GPVI

Phase I completed

DZ-697b

GPVI

Phase I completed

AJW200

vWF

Phase I

ARC1779

vWF

Phase II

ARC15105

vWF

Preclinical

ALX-0081

vWF

Phase II

ALX-0681

vWF

Phase II

82D6 A3

vWF

Preclinical

Z4 A5

GPIIb-IIIa

Preclinical

DG-041

PGE2

Phase II
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BX 667 is an orally active reversible P2Y12 receptor
antagonist that is metabolized by esterases to form the
carboxylic active form, BX 048.34 In-vitro, ADP-induced
aggregation is potently inhibited by BX 667. Additionally,
administration of BX 667 results in a rapid and sustained
inhibition aggregation.35 This observation is also supported
by the intravenous BX 048 and oral BX 667 administration in
rat arteriovenous-shunt model which showed a similar pharmacodynamic relationship between the plasma concentration
of BX 048 and thrombus inhibition.34 This antagonist has yet
to be evaluated in healthy human subjects.

Glycoprotein antagonists
αIIbβ3 antagonists
Glycoprotein GPIIbIIIa (αIIbβ3) is the most abundant integrin on the platelet surface.36 αIIbβ3 is known to be involved in
both inside-out or outside-in platelet signaling. The inside-out
signaling in platelet activation involves the various signaling
pathways that converge into a common signaling endpoint
that leads to the activation of integrin αIIbβ3.37 Ligand
binding of fibrinogen or von Willebrand factor (Vwf) to
αIIbβ3 mediates platelet adhesion and aggregation, triggers
outside-in integrin activation and results in additional granule
secretion, stabilization of platelet adhesion, aggregation, and
clot retraction.37
Abciximab (ReoPro®; Eli Lilly) is an antibody developed from the murine human chimera c7E3 Fab, which
targets the integrin αIIbβ3,38 preventing integrin binding
to fibrinogen and Vwf. Abciximab rapidly binds with high
affinity and has a slow rate of dissociation from its target.39
In addition, abciximab binds with high affinity to αvβ3
(vitronectin receptor)40 and low affinity to the leukocyte
MAC-1 receptor.41 Initial intravenous administration enables
rapid onset of platelet inhibition.42 As abciximab has an
extremely short half-life,43 platelet aggregation returns to
baseline levels within 12–24 hours following discontinuation
of therapy.44,45 Interestingly, the ISAR-REACT trial demonstrated no additional benefit of abciximab over placebo
in the reduction of ischemic complications or mortality.43,46
Similarly, among diabetic patients without elevated troponin
levels undergoing elective PCI, no difference was observed
in primary endpoint events between abciximab and placebo/
clopidogrel groups.47 Conversely, in patients with elevated
troponin levels, the incidence of mortality and recurrent
ischemic complications was significantly reduced with
abciximab.48 Careful monitoring must be accompanied with
the administration of abciximab as bleeding and thrombocytopenia have been observed.49–51
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Eptifibatide (Integrilin®, Millenium Pharmaceuticals,
Cambridge, MA/Schering-Plough, Kenilworth, NJ) is a
cyclic heptapeptide derived from snake venom that contains
a KGD (lysine-glycine-aspartic acid) sequence which selectively recognizes αIIβ3.52 The IMPACT-II study showed that
a single loading dose followed by continuous infusion for
20–24 hours only resulted in 50% αIIbβ3 receptor blockade; thus, limited benefits and efficacy through eptifibatide
were observed.53 The ESPRIT trial, however, which utilized
intravenous administration of a double bolus54 followed by
maintenance infusion, significantly reduced the 30 days
incidence of death, MI, and target vessel revascularization,55
establishing the clinical efficacy for this drug. These observations were confirmed in the PURSUIT trial, which showed
an absolute reduction in the 30-day incidence of death and
MI on eptifibatide.56 Despite the reduction in mortality, the
ACUITY trial also showed an increase incidence of major
bleeding in patients with ACS undergoing PCI.57,58
Tirofiban (Aggrastat®, Merck, Whitehouse Station, NJ) is
a tyrosine-derivative nonpeptide mimetic reversible inhibitor
of αIIbβ3 that specifically and competitively binds to the
receptor. Treatment with tirofiban in combination with aspirin
and heparin in patients with ACS significantly reduced the
30-day post-treatment incidence of death, MI, or recurrent
ischemia.59 Further, tirofiban was superior for ACS patients
recovering from invasive coronary angiography.59 As for the
use of tirofiban as an adjunct to PCI, tirofiban was shown
to be inferior to abciximab in the RESTORE and TARGET
trials where the incidence of composite death, nonfatal MI,
and urgent target vessel revascularization were higher with
tirofiban or abciximab at 30 days.60
Z4 A5 is a novel αIIbβ3 peptide antagonist that is currently
in development. This antagonist has been shown to inhibit
platelet-induced aggregation and thrombi formation. Additionally, when Z4 A5 was examined along with heparin and/
or aspirin in the rabbit arteriovenous shunt thrombosis model,
it was shown to be an effective antithrombotic agent when
administered with aspirin.61 The pharmacodynamics and pharmacokinetics in humans are currently under investigation.61

Additional glycoprotein antagonists
Additional glycoprotein targets have received a fair amount
of attention in the drive to develop novel approaches for
antiplatelet intervention. The Vwf, a multimeric glycoprotein
that acts as a bridging element between damaged endothelial
sites and the glycoprotein receptors on platelets, is one such
target. The A1 and A3 domains of Vwf bind to collagen, while
the A1 domain is bound to the GPIb-IX-V platelet receptor
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complex.62,63 Vwf also binds to active αIIbβ3 on the platelet
surface. Interactions between αIIbβ3 and Vwf contribute
to the final, irreversible binding of platelets to the subendothelium and play a leading role in platelet aggregation.64
A second target receiving attention as a potential site for
antiplatelet therapy is the collagen receptor glycoprotein VI
(GPVI). The collagen-GPVI interaction triggers subsequent
tyrosine phosphorylation of the immunoreceptor tyrosinebased activation motif of the Fc receptor γ chain, activating
the Syk kinases pathway, LAT, SLP-76, and phospholipase
Cγ2,65 resulting in platelet activation or aggregation.

Vwf antagonists
AJW200 is an IgG4 humanized monoclonal antibody to Vwf
which has been shown to specifically inhibit high-shearstress-induced platelet aggregation in a concentration-dependent manner in vitro in blood from human volunteers.66
ARC1779 (Archemix Corp, San Francisco, CA) is an
aptamer-based antagonist. This second generation nucleaseresistant aptamer is conjugated to a 20-Kda polyethylene glycol and binds with high affinity to the active Vwf A1-domain
and inhibits Vwf-dependent platelet aggregation.67 A Phase
II trial demonstrated that continuous infusion of ARC1779
effectively increased platelet counts in critically ill thrombotic
thrombocytopenic purpura patients by preventing platelet
aggregation and loss of platelets. Cessation of ARC1779 infusion resulted in platelet count reduction and progression of
thrombotic thrombocytopenic purpura-related organ damage.68 This drug is currently under clinical investigation.
Other Vwf antagonists in clinical development or investigations include ARC15105, ALX-0081 (Ablynx), ALX-0681,
and 82D6 A3. ARC15105 is a chemically advanced aptamer
with assumed higher affinity to Vwf, but less specific inhibitor of Vwf-dependent platelet aggregation than ARC1779,
based on ex-vivo trials.69 The preclinical and clinical trials
have shown that ALX-0081, a bivalent humanized nanobody
that recognizes the Glycoprotein Ib (GPIb) binding site of
Vwf, is a potent and safe inhibitor of Vwf-mediate platelet
aggregation over a wide range of doses when administered
in combination with aspirin, heparin, and clopidogrel. ALX0081 is currently under investigation in PCI patients in a
Phase II trial. 82D6 A3, a monoclonal antibody directed
against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016,
Ser-1020, Met-1022, and His-1023 of the Vwf A3 domain,70
was shown to result in complete inhibition of Vwf binding
to collagen during the first 3 days after stent implantation
in baboons.71 Further trials will need to follow to verify
82D6 A3 efficacy, safety, and tolerability.
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GPVI receptor antagonists
PR-15 (Revacept®, ABX-CRO/Medifacts GmbH, Goerlitz, Saxony, Germany) is a soluble, dimeric glycoprotein
(GPVI)-Fc that has been shown to adhere to exposed collagen in endothelial lesions preventing the binding to platelet
GPVI receptors. Collagen-induced human platelet adhesion
or plaque formation were significantly reduced with pretreatment of soluble GPVI-Fc.72,73 Similarly, infusion of
GPVI-Fc was shown to virtually abolish stable arrest and
aggregation of platelets following vascular injury in mice.65
Subsequently, a Phase I clinical trial demonstrated that intravenous administration of PR-15 is safe and well tolerated by
healthy volunteers.74
DZ-697b is an orally active collagen and ristocetin inhibitor. Safety and efficacy have been assessed in a Phase I trial
which showed potential benefits such that bleeding time was
substantially shortened compared with clopidogrel treatment.75 DZ-697b is currently under clinical investigation.

GPIb receptor antagonists
Novel targets still under investigation include h6B4-Fab,
GPGP-290, and SZ2. h6B4-Fab is a murine monoclonal
antibody, derived from the humanized Fab fragment of 6B4
targeting GPIbα and neutralizes the binding site of the Vwf
A1 domain.76,77 6B4 has been shown to inhibit platelet adhesion by competing with Vwf for binding to GPIbα under
high-shear conditions. Moreover, preliminary data show 6B4
has no effect on platelet count or bleeding times in vivo in
baboons, but dose- and time-dependently inhibited ristocetininduced platelet aggregation.78 GPG-290 is a recombinant,
chimeric antibody purified from Chinese hamster ovary cell
culture that contains the amino-terminal 290 amino acids
of GPIbα linked to the human IgG1. GPG-290 treated dogs
were shown to exhibit prolonged bleeding compared with
the clopidogrel-treated control, despite the prevention of
coronary artery thrombosis.79 SZ2, a monoclonal antibody
developed against GPIbα, has also been shown to inhibit
both ristocetin- and botrocetin-induced platelet aggregation
in vitro.80 Preclinical investigations are still underway to
determine the in-vivo efficacy of SZ2.

Phosphodiesterase antagonists
Platelets express three phosphodiesterase (PDE) isoenzymes,
PDE 2, 3, and 5. PDEs regulate the levels of 3,5′-cyclic adenosine monophosphate (Camp) and 3′,5′-cyclic guanosine
monophosphate (Cgmp) by catalyzing the hydrolysis of
Camp and Cgmp to inactive 5′-AMP and 5′-GMP, respectively.81 Platelet activation relies on degradation of Camp
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and Cgmp; hence regulating these secondary messengers
is fundamental in regulating platelet activation and
thrombosis.
Cilostazol (Pletal®, Otsuka Pharmaceutical Co, Tokyo,
Kapan) is a type III PDE (PDE3) selective oral inhibitor.82
Liu and colleagues have shown that cilostazol enhances the
interstitial concentration of adenosine in several in-vitro
and in-vivo models83 by inhibiting adenosine uptake. This
in turn stimulates A2 receptors, which further increases
Camp levels. As a result, platelet-induced aggregation is
reversibly inhibited by cilostazol.84 Cilostazol is extensively
metabolized by CYP3 A4, while CYP2C19 is also shown
to have a minor role in cilostazol metabolism.85 Cilostazol
is safe and effective in reducing the incidence of repeated
revascularization after PCI and risk of restenosis; however,
this drug does not show superiority in reducing the primary
composite endpoints of adverse cardiovascular events after
drug-elution stent implantation.86 Despite the functional
implications of adjunctive treatment with cilostazol compared
with standard aspirin and clopidogrel treatment, as shown in
the OPTIMUS-2 study, the accompanied side effects (headaches, gastrointestinal symptoms, and skin rash) often lead
to the discontinuation of the drug.87
Dipyridamole (Aggrenox ®, Boehringer Ingelheim,
Ingelheim, Germany) is a pyridopyrimidine derivative with
both antiplatelet and vasodilator properties.88 Similar to
cilostazol, dipyridamole inhibits cyclic nucleotide phosphodiesterase and blocks adenosine uptake, which results in
increased Camp.89 The ESPS-2 and ESPRIT trials showed
that dual treatment of dipyridamole and aspirin reduced risk
of stroke or death by 37% compared with aspirin alone.90,91
Based on the ESPRIT and ESPS-2 trials, dipyridamole has
been FDA approved for stroke prevention.91

Thromboxane A2 receptor
antagonists

Platelets express the thromboxane receptor α (TPα), a GPCR
that is coupled to Gq and G12/13 and signals platelet activation
through a number of intracellular pathways which converge
to reinforce primary platelet activation through thrombin or
collagen.92
S18886 (terutroban) is an oral reversible inhibitor of TPα.
In preclinical studies, S18886 dose-dependently prolonged
occlusive thrombus formation in animal models, but did not
alter the size of the myocardial infarct size in the ischemiaperfusion model. S18886 and clopidogrel were effective in
preventing occlusive thrombus formation with a moderate
increase in bleeding time.93 Subsequently, however, in the
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Phase III clinical trial (PERFORM), S18886 did not meet
the predefined criteria for noninferiority since S18886 and
aspirin had similar rates of protection without safety advantages for S18886.94
Z-335 ((+/-)-sodium[2-(4-chlorophenylsulfonyl-amino
methyl)indan-5-yl]acetate monohydrate) is an oral TPα
antagonist that has previously been shown to dose-dependently inhibit the specific binding of [3H]SQ-29548 (TPα
inhibitor) to human and guinea pig platelet membranes.95
In healthy male Japanese volunteers, Z-335 inhibited
U46619-induced platelet aggregation within 2 hours of
administration.96
BM-573, another investigational inhibitor that targets
TPα, has been shown to halt the progression of atherosclerosis in low-density lipoprotein receptor deficient mice.97
Preclinical models have shown that arachidonic acid-induced
aggregation is completely inhibited in the presence of
BM-57398 and clinical studies on this compound are currently ongoing.

Thrombin receptor antagonists
Thrombin activates human platelets via two protease activated
receptors (PARs), PAR1 and PAR4. PAR activation leads to
a diverse range of pro-thrombotic signaling events mediated
through Gq, G12/13, and possibly Gi, resulting in phospholipase
β activation, Rho activation, and adenyl cyclase inhibition,
respectively. PAR activation requires thrombin cleavage of the
amino terminus of the receptor, revealing a tethered ligand.
While it has been challenging to develop an inhibitor that
can directly compete with the endogenous tethered ligand,
development of PAR1 inhibitors as a therapeutic target to
minimize uncontrolled platelet activation has recently been
investigated.
SCH 530348 (Vorapaxar®, Merck and Co, Whitehouse
Station, NJ) is an orally active synthetic analog of himbacine99 that competitively binds with high affinity to the
PAR1. Previous in-vitro assays show SCH 530348 inhibited
thrombin- and thrombin receptor activating peptide-induced
platelet aggregation, without affecting the aggregation
induced by ADP, U46619, or collagen. In addition, SCH
530348 did not affect the prothrombin and activated partial
thromboplastin time, suggesting that bleeding time may not
be increased. Pre-clinically, cynomolgus monkeys treated
with SCH 530348 alone or in addition with aspirin and
clopidogrel, showed no increase in bleeding times.100 The
TRA-PCI study verified that addition of SCH 530348 to
standard antiplatelet therapy (aspirin and clopidogrel) was
not associated with increases in thrombolysis in MI (TIMI)
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or bleeding compared with the control group.101 The Phase III
clinical trials TRA-CER and TRA 2ºP-TIMI, which sought
to assess the impact of vorapaxar on cardiovascular death,
MI, stroke, and recurrent vascular events in patients with
established coronary, cerebral, or peripheral atherosclerosis102
failed due to unforeseen intracranial bleeding.102
Preclinical trials showed that oral administration of the
PAR1 antagonist, E5555 (Atopaxar®, Eisai Co Ltd, Tokyo,
Japan), significantly prolonged bleeding times in guinea
pigs.103 Further, PECAM-1, active αIIbβ3, GPIb, thrombo
spondin, and vitronectin expression were significantly
reduced by E5555 in whole blood flow cytometry. Clinical
studies have shown that E5555 attenuated thrombin-induced
but not ADP-induced platelet aggregation.104,105
Additional PAR-1 antagonists SCH 205831 and SCH
602539 are still under investigation. Preliminary data show
SCH 205831 derived from himbacine inhibited platelet deposition in baboons with arteriovenous-shunt thrombosis. Similarly, SCH 602539 inhibited thrombosis in a dose-dependent
manner in the Folts model of thrombosis in anesthetized
cynomolgus monkeys.106 These compounds continue to be
developed in preclinical models.

Conclusion
Significant progress has been made in advancing our understanding of how platelet activation directly regulates thrombus formation in the vessel leading to occlusive thrombi and
stroke. However, a continued need for the development of
new antiplatelet therapies exists as the risk for MI, stroke,
and death, remain a persistent problem for individuals suffering from cardiovascular disease. Further, while aspirin
continues to be the first line of pharmacological intervention
in antiplatelet therapy, the risk of bleeding is significantly
exacerbated by its irreversible action coupled to the additional regimen of dual therapy often employed to minimize
thrombotic events. In hopes of reducing prolonged bleeding
or myocardial infarct events, newer compounds continue to
be developed to target alternative sites in the platelet. The
successful implementation of these strategies may significantly reduce the morbidity and mortality in cardiovascular
disease due to unwanted platelet activation as well as excessive bleeding due to traditional approaches. Even with the
newer antiplatelet drugs entering the market in the near
future, we are faced with the realization that activation of the
platelet involves an increasingly complex signaling network.
Hence, new frontiers will need to be explored which will
take advantage of this signaling to reveal novel therapeutic
targets with diminished off-target effects.
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